Objective iof ithe ipresent iwork iis ito idevelop iorodispersible itablets iof iSalbutamol i ito iimprove ibioavailability, idisintegration itime, idissolution iefficacy iand ipatient icompliance. iOrodispersible itablets iare ithe ifast igrowing iand ihighly iaccepted idrug idelivery isystem iin inow idays imainly ito iimprove ipatient icompliance. iOrodispersible itablets ihave inumber iof iadvantages iover iconventional idosage iforms, ibecause iof ithat iOrodispersible itablets ihave iemerged ias ian ialternative ito iconventional idosage iforms. Orodispersible itablets idissolve ior idisintegrates iinstantly ion ithe ipatient itongue ior ibuccal imucosa. iOrodispersible itablets iof isolbutamol i iwere iprepared iusing isuperdisintegrants, iCrospovidone,Mannitol (Pearlitol iSD-200), ias idiluents iby idirect icompression imethod. iNine iformulations iwere iprepared iusing ithe isuperdisintegrants iat ilower, iintermediate i& ihigher iconcentration. iMannitol iis iused ito ienhance ithe iorganoleptic iproperties iof itablets. iTablets iwere ievaluated ifor iuniformity iof iweight, ihardness, ifriability, iwater iabsorption iratio, idispersion itime, idisintegration itime iand iin ivitro idrug irelease. iAll ithe iformulations ishowed idisintegration itime iless ithan i33 mins iand idrug irelease iby idissolution i(100% iat ithe iend iof i10 imins).

No abstract

Regulated drug release in zero-order manner attained in the current study indicates that the optimized Sustained Release tablet of Voriconazole, prepared using HPMC K100M as a polymer, ethyl cellulose, Sodium CMC and lactose used as a diluents. Magnesium stearate was used as a lubricant and Talc was used as a glident. These sustained release tablets can release the drug up to 12 hours in predetermined rate. The formulated powder blend was evaluated for bulk density, tapped density, compressibility index and angle of repose. The formulated tablets were evaluated for physical characteristics of sustained release tablets such as thickness, hardness, friability, weight variation and drug content. The results of the formulations found to be within the limits specified in official books. The tablets were evaluated for In-vitro drug release studies by using USP type I dissolution test apparatus. The dissolution test was performed in 0.1 N HCL for 2 hr and phosphate buffer pH 6.8 for 10hrs.The in-vitro cumulative drug release profile of all formula-tions F1-F10 at 12 hours showed 97.35% to 99.56% drug release, respectively. From the data it was clear that by increasing the amount of polymer in the formulation the amount of drug release was decreased. Hence, Formulation F7 was the most promising formulation as it gives satisfactory release (99.56%) for 12 hours and F7 found to be the best formulation.